Ranbaxy gets USFDA approval for carvedilol tablets

Pharmaceutical giant Ranbaxy on Monday said that it has received tentative approval from the US Food and Drug Administration to manufacture and market carvedilol tablets for treatment of cardiac disorders including hypertension.

The total market sales for generic drug, carvedilol tablets, 3.125 mg, 6.25 mg, 12.5 mg and 25 mg - are estimated at around $ 729 million, a company release said.

The new drug is used for the treatment of congestive heart failure, left ventricular dysfunction following myocardial infraction and hypertension, it said.